上海市锦天城律师事务所 关于上海凯赛生物技术股份有限公司 2025 年第一次临时股东大会的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于上海凯赛生物技术股份有限公司 2025 年第一次临时股东大会的 1 法律意见书 致：上海凯赛生物技术股份有限公司 根据《中华人民共和国证券法（2019 年修订）》（以下简称"《证券法》"） 《中华人民共和国公司法（2023 修订）》（以下简称"《公司法》"）和中国 证券监督管理委员会《上市公司股东会规则》等法律、法规和其他有关规范性文 件的要求，上海市锦天城律师事务所（以下简称"本所"）接受上海凯赛生物技 术股份有限公司（以下简称"凯赛生物"或"公司"）的委托，指派律师参加公 司 2025 年第一次临时股东大会（以下简称"本次股东大会"或"本次会议"）。 上海市锦天城律师事务所 法律意见书 为出具本《法律意见书》，本所声明如下： 1、本所律师仅对本次股东大会的召集程序、召开程序、出席会议人 ...

Core Viewpoint - The article highlights the increasing presence and application of bio-based materials at the CHINAPLAS 2025 International Rubber and Plastics Exhibition, indicating a shift towards high-end and significant use cases beyond single-use products and packaging, signaling a burgeoning industry ready for growth [1]. Group 1: Company Innovations - Jinhai Technology is exploring a "recycling + bio-based" composite technology path, using bio-based BDO to replace part of petroleum-based raw materials, resulting in a chemical recycling PBT resin with a bio-based content of 31% [4]. - Kasei Biotech focuses on bio-based materials for low-carbon applications in automotive lightweighting, electronics, industrial products, rail transportation, and consumer goods, showcasing innovations in battery boxes, structural components, and thermal management systems [9]. - Arkema presents a series of bio-based, recyclable, lightweight, and high-durability specialty material solutions aimed at low-carbon living and advanced manufacturing [15]. Group 2: Material Applications - Kasei's bio-based polyamide materials are innovatively applied in various sectors, including electric vehicle battery boxes and interior/exterior components [9]. - Rilsan® PA11 from Arkema, derived from castor beans, is 100% bio-based and fully recyclable, with a carbon footprint reduced to 1.3 kg CO2e/kg, approximately 80% less than conventional petroleum-based polyamides [22]. - SK Chemicals has developed bio-based PU foam shoe uppers made from ECOTRION, showcasing the versatility of bio-based materials in footwear [26]. Group 3: Exhibition Highlights - The exhibition features a wide array of bio-based innovations, including CovationBio's bioPTMEG, a bio-based alternative to petroleum-based PTMEG, demonstrating excellent durability and elasticity for high-performance applications [34]. - Leaf Bio showcases its core exhibits, including 100% bio-based polyester PEF bottle chips and BioFleax™ fibers, emphasizing environmental and comfort characteristics for diverse applications [37]. - eSUN highlights its environmentally friendly materials based on PLA, including fibers, yarns, and biodegradable packaging applications, showcasing the potential of bio-based materials in various sectors [38]. Group 4: Future Events - The 10th Bio-based Conference and Exhibition will take place from May 25 to May 27, 2025, in Shanghai, featuring discussions on bio-based industry strategies, innovations in key chemicals and materials, and sustainable applications across various sectors [70][72].

上海凯赛生物技术股份有限公司 上海凯赛生物技术股份有限公司 关于股东大会开设网络投票提示服务的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海凯赛生物技术股份有限公司（以下简称"公司"）拟于 2025 年 5 月 16 日 14:00 召开 2025 年第一次临时股东大会，本次会议采用现场投票和网络投票 相结合的表决方式，详见公司于 2025 年 4 月 15 日在上海证券交易所网站 （www.sse.com.cn）披露的公司《关于召开 2025 年第一次临时股东大会的通知》 （公告编号：2025-018）。 为更好地服务广大中小投资者，确保有投票意愿的中小投资者能够及时参会、 及时投票，公司拟使用上证所信息网络有限公司（以下简称"上证信息"）提供 的股东大会提醒服务，委托上证信息通过智能短信等形式，根据股权登记日的股 东名册主动提醒股东参会投票，向每一位投资者主动推送股东大会参会邀请、议 案情况等信息。投资者在收到智能短信后，可根据《上市公司股东会网络投票一 键通服务用户使用手册》（下载链接：https://vot ...

证券代码：688065 证券简称：凯赛生物 公告编号：2025-024 上海凯赛生物技术股份有限公司 关于召开 2024 年度暨 2025 第一季度 业绩说明会的公告 一、说明会类型 本次投资者说明会以视频结合网络互动召开，公司将针对 2024 年度及 2025 年第一季度的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在 信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 5 月 15 日（星期四）10:00-11:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2025 年 5 月 9 日（星期五）至 5 月 14 日（星期三）16:00 前登 录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " ...

证券代码：688065 证券简称：凯赛生物 公告编号：2025-025 上海凯赛生物技术股份有限公司 关于召开 2025 年上海辖区上市公司年报 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 5 月 15 日 （星期四） 15:00-16:30 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2024 年度的经营成果 及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内 就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2025 年 5 月 15 日（星期四）15:00-16:30 （二）会议召开地点：上证路演中心 （三）会议召开方式：上证路演中心网络互动 三、参加人员 董事长、总裁：刘修才博士 投资者可 ...

上海凯赛生物技术股份有限公司 2025 年第一次临时股东大会会议资料 证券代码：688065 证券简称：凯赛生物 中国·上海 二〇二五年五月十六日 上海凯赛生物技术股份有限公司 2025 年第一次临时股东大会 目 录 | 上海凯赛生物技术股份有限公司 | 2025 | 年第一次临时股东大会会议须知 2 | | --- | --- | --- | | 上海凯赛生物技术股份有限公司 | 2025 | 年第一次临时股东大会议程 4 | | 议案一：关于变更公司注册资本、修订《公司章程》的议案 5 | | | | 议案二：关于选举公司第二届董事会非独立董事候选人的议案 7 | | | 1 上海凯赛生物技术股份有限公司 2025 年第一次临时股东大会 上海凯赛生物技术股份有限公司 地址：中国（上海）自由贸易试验区蔡伦路 1690 号 5 幢 邮编：201203 电话：86-21-50801916 传真：86-21-50801386 网站：http://www.cathaybiotech.com 上海凯赛生物技术股份有限公司 2025 年第一次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事 ...

Core Viewpoint - The article emphasizes the importance of scaling and cost-effectiveness in the bio-manufacturing industry to compete with traditional manufacturing sectors, particularly the chemical industry, and to achieve carbon neutrality goals [6][10][12]. Group 1: Key Elements of Bio-Manufacturing - Bio-manufacturing is positioned as a manufacturing sector that aims to replace traditional industries, particularly chemicals and inorganic materials [6][10]. - The success of high-tech industries relies heavily on research and development investments, which must be supported by companies possessing core technological capabilities [6][7]. - Intellectual property protection is crucial for fostering innovation and ensuring that companies can profit from their research investments [8][9]. - The supply of raw materials is a significant challenge, as bio-manufacturing must find reliable and stable sources of biomass that do not compete with food supplies [9][10]. Group 2: Resource Factors - Current bio-manufacturing resources primarily include food crops and biomass, with high-energy raw materials like palm oil and soybeans being expensive [13][17]. - Corn is the main raw material for bio-manufacturing globally, but its use in China is limited due to population pressures [17][19]. - The industry faces challenges in utilizing agricultural waste effectively, with many attempts resulting in commercial failures [17][19]. Group 3: Cost Factors - Selecting the right projects is essential to minimize trial and error costs in bio-manufacturing [20][22]. - The bio-manufacturing industry must compete with fossil fuels, and the energy density of bio-based materials is inherently lower than that of traditional chemical products [21][22]. - The cost structure of bio-manufacturing in China is competitive due to lower labor and investment costs compared to the US and Europe [28][30]. Group 4: Market Factors - New bio-manufactured products face significant market entry challenges, including user risk perceptions and complex value chains [31][33]. - The competition is not only from peers but also from established fossil fuel industries, which dominate market standards and decision-making processes [37][38]. - There are negative perceptions about bio-manufacturing being small-scale and high-cost, which can hinder investment and market acceptance [38][40]. Group 5: Recommendations for Bio-Manufacturing in Hainan - Companies should consider competitive energy solutions and the availability of raw materials when establishing bio-manufacturing projects in Hainan [48][49]. - The government should facilitate market access for bio-manufactured products to encourage early adoption and create demonstration cases [49][50].

Core Viewpoint - The article discusses the establishment and growth of Hefei Hydrogen He, a joint venture focused on bio-based materials, highlighting its strategic partnerships and financial performance of its parent company, Kaisa Bio [1][5]. Company Overview - Hefei Hydrogen He was registered on April 9, 2025, in the Hefei area of the China (Anhui) Free Trade Pilot Zone, with a registered capital of 20 million RMB, where Kaisa Bio holds a 55% stake [1]. - The legal representative of Kaisa Bio is Zhang Hongguang, who has been the Vice President since August 2019 [2]. Shareholding Structure - Kaisa Bio holds 55% of Hefei Hydrogen He, contributing 11 million RMB, while 3P.COM Corporation from South Korea holds 45%, contributing 9 million RMB [3]. Strategic Partnerships - In January 2024, Kaisa Bio signed an agreement with 3P.COM to establish a joint venture focusing on thermoplastic bio-based polyamide composite materials for hydrogen storage and transportation, urban air mobility, and wind turbine blades [3]. - Kaisa Bio has also established several other companies, including a joint venture with Ningde Times and Calai Composites, focusing on bio-based composite materials for battery casings and automotive parts [4]. Financial Performance - Kaisa Bio reported a total revenue of 2.958 billion RMB for 2024, marking a year-on-year increase of 39.91%, and a net profit of 489 million RMB, up 33.41% from the previous year [5]. Product Capacity and Sales - Kaisa Bio's total production capacity for various bio-based materials reached nearly 300,000 tons by the end of 2024, with specific capacities as follows: - Bio-based long-chain dicarboxylic acid: 115,000 tons [6] - Bio-based pentamethylenediamine: 50,000 tons [7] - Bio-based polyamide: 100,000 tons [8] - Bio-based continuous fiber thermoplastic composite materials [9]. - The main revenue sources for 2024 were long-chain dicarboxylic acid products, generating 2.670 billion RMB, and bio-based polyamide products, generating 144 million RMB [9]. Application Expansion - In March 2024, Kaisa Bio signed a cooperation agreement with China Merchants Highway and China Merchants Jinling to establish a joint laboratory for bio-based new materials, aiming to enhance performance and reduce costs in highway and green energy materials [11]. - Kaisa Bio provided low-carbon, high-performance composite materials for Qingdao Honghu Aviation Technology's RAP-AT1 active temperature-controlled container, which has entered commercial use [12].

证券代码：688065 证券简称：凯赛生物 公告编号：2025-023 上海凯赛生物技术股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 三、其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等相关规定及公司回购股份方案，在回购期限内根据 市场情况择机做出回购决策并予以实施，并根据回购股份事项进展情况及时履行信 息披露义务，敬请广大投资者注意投资风险。 一、回购股份的基本信息 2024 年 10 月 21 日，公司召开第二届第二十四次董事会会议，审议通过了 《关于以集中竞价交易方式回购公司股份的方案》，同意公司使用自有资金或自 筹资金以集中竞价交易方式回购公司股份，回购资金总额不低于人民币 1,000.00 万元（含），不超过人民币 2,000.00 万元（含），回购价格不超过 67 元/股 （含），回购期限自董事会审议通过本次回购方案之日起 12 个月内。具体内容详 见公司于 2024 年 10 月 22 ...

证券代码：688065 证券简称：凯赛生物 公告编号：2025-023 上海凯赛生物技术股份有限公司 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，现将公司回购股份情况公告如下： 2025 年 4 月 30 日，公司通过上海证券交易所交易系统以集中竞价交易方式 回购公司股份 230,366 股,占公司总股本 721,289,794 股的比例为 0.0319%。回购 成交的最高价为 53.40 元/股，最低价为 44.08 元/股，支付的资金总额为人民币 10,497,716.71 元（不含印花税、交易佣金等交易费用)。 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 截至 2025 年 4 月 30 日，上海凯赛生物技术股份有限公司（以下简称"公 司"）通过上海证券交易所交易系统以集中竞价交易方式回购公司股份 230,366 股,占公司总股本 721,289,794 股的比例为 0.0319%。回购成交的最高 ...